Search

α 2 -macroglobulin (α 2 M) is a versatile endopeptidase inhibitor that plays a role in cell growth, inflammation and coagulation. α 2 M is an inhibitor of key coagulation enzyme thrombin. Hypercoagulability due to an excess of thrombin production can cause thrombotic events. Therefore, we investigated the association of α 2 M levels and cardiovascular events in a subset of the general Italian population. We determined α 2 M levels in the baseline samples of a prospective cohort (n = 19,688; age: 55 ± 12 years; 47.8 % men) of the Moli-sani study and investigated the association with the cardiovascular events (n = 432, 2.2 %) in the median follow-up period of 4.3 years. Hazard ratios (HR) with 95 % confidence intervals (CI) were calculated by multivariable Cox regression and adjusted for a large panel of confounding factors. α 2 M levels above the 90th percentile were significantly associated with cardiovascular disease (CVD) events after full adjustment for age, sex, current smoking, BMI, oral contraceptive use, cardiovascular diseases, hypertension, hypercholesterolemia, diabetes and history of cancer (HR: 1.36; CI: 1.06–1.74). Moreover, high α 2 M was associated with coronary heart disease (CHD; HR: 1.47; CI: 1.12–1.91), but not stroke. Stratification for CVD at baseline showed that high α 2 M levels are associated with CHD events in subjects without CVD at baseline (HR: 1.40; CI: 1.00–1.95) and subjects with CVD at baseline (HR: 1.58; CI: 1.02–2.44). We show in a prospective cohort that high levels of α 2 M could be a risk factor for cardiovascular events, especially coronary heart disease events. • Alpha 2 -Macroglobulin and cardiovascular events are associated. • High α 2 M is a risk factor for coronary heart disease. • The association is independent of age, sex, and lifestyle. [ABSTRACT FROM AUTHOR]